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Abstract
The cyclic adenosine monophosphate (AMP) re-
sponse element-binding protein, CREB, often modu-
lates stress responses. Here, we report that CREB
suppresses the glioblastoma proliferative effect of the
stress-induced acetylcholinesterase variant, AChE-R.
In human U87MG glioblastoma cells, AChE-R formed a
triple complex with protein kinase C (PKC) E and the
scaffold protein RACK1, enhanced PKCE phosphor-
ylation, and facilitated BrdU incorporation. Either over-
expressed CREB, or antisense destruction of AChE-R
mRNA, PKC, or protein kinase A (PKA) inhibitors—but
not CREB combined with PKC inhibition suppressed—
this proliferation, suggesting that CREB’s repression
of this process involves a PKC-mediated pathway,
whereas impaired CREB regulation allows AChE-R–
induced, PKA-mediated proliferation of glioblastoma
tumors.
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Introduction
Glioblastoma multiforme (GBM), the most common primary
brain tumor, carries a grave prognosis, despite aggressive
treatment [1]. However, the mechanisms underlying GBM
pathogenesis and poor response to conventional therapy
are yet unclear. GBMs commonly overexpress both the
platelet-derived growth factor receptor and the epidermal
growth factor receptor and their ligands [2]; the latter can
activate various signaling pathways associated with glio-
blastoma cell survival and tumor formation [3]. Also, GBMs
either overexpress or lose expression of various protein
kinase C (PKC) isoforms implicated in cell proliferation and
invasion [4]. In particular, various stress signals, growth
factors, and kinases promote phosphorylation-mediated
activation of the cyclic adenosine monophosphate (AMP)
response element-binding transcription factor, CREB, in-
volved in glial cell fate determination [5,6]. As some of these
signals also induce expression of the acetylcholinesterase
variant AChE-R [7] and because AChE-R is involved in
glioblastoma proliferation [8], we explored the possibility
that these effects are interrelated. The three 3V splice variants
of AChE have distinct noncatalytic activities (reviewed in Ref.
[7]; Figure 1A). The ‘‘synaptic’’ (tailed) isoform, AChE-S, is the
principal AChE variant in the brain and muscles and its C-
terminus is encoded by the open reading frame in exon (E) 6.
AChE-E, the ‘‘erythrocytic’’ (hydrophobic) isoform, links E4 and
E5 to encode a different 43–amino acid C-terminal peptide,
which is anchored through a glycophosphoinositide moiety to
erythrocyte surface membranes. The ‘‘readthrough’’ isoform,
AChE-R, expressed in embryonic and tumor cells possesses a
C-terminus encoded by intron 4. AChE-R is overproduced
under psychological stress in response to AChE inhibitors
and in myasthenic muscles, all of which are under cholinergic
imbalance [7–9]. We have recently shown that AChE mRNA
accumulates in primary human astrocytomas in correlation with
these tumors’ grade of aggressiveness, which further associ-
ates with an mRNA splicing shift from AChE-S to the AChE-R
transcript [10]. In the present study, we further investigate the
function of the R-splice variant in cell proliferation and the
signaling molecules that mediate AChE-R’s effect. Here, we
report that in human glioblastoma cells, CREB, a common
downstream target for multiple signaling pathways, is an intrin-
sic repressor of PKCq-mediated AChE-R–induced prolifera-
tion, and demonstrate how this function may fail under drastic
excess of AChE-R. Under PKC inhibition, which blocks CREB’s
repression, AChE-R may still promote proliferation, probably
through a protein kinase A (PKA)-mediated pathway.
Materials and Methods
Cell Cultures and Transfection
Human glioblastoma U87MG and COS1 cells were grown in
Dulbecco’s modified Eagle’s medium (Biological Industries,
Beit Ha’emek, Israel) with 10% fetal calf serum (FCS) and
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2 mM L-glutamine at 37jC and 5% CO2-humidified chamber.
PC12 cells were grown in Dulbecco’s modified Eagle’s
medium with 10% FCS, 8% donor horse serum (DHS), and
2 mM L-glutamine. Transfections involved 0.4 or 12 mg of
plasmid DNA per well in 48-well plates or 25-cm2 flasks
(using Lipofectamine Plus; Gibco BRL Life Technologies,
Bethesda, MD) of either human AChE-R, AChE-S [8] or
CREB expression vectors [11], or AChE-R and CREB to-
gether. The nonrelevant pEGFP-C2 plasmid (Clontech Lab-
oratories, Palo Alto, CA) served as control.
Nuclear Protein Extractions
Nuclear and cytoplasmic protein extracts were prepared
from U87MG cells 24 hours posttransfection. Cells were
washed twice in phosphate-buffered saline (PBS), scraped,
precipitated by centrifugation (1000 rpm, 5 minutes), then
rewashed in PBS. Precipitates were incubated with com-
plete miniprotease inhibitor cocktail (Roche Diagnostics
GmbH, Mannheim, Germany) and 150 ml of buffer A
(10 mM Tris–HCl, pH 7.4, 10 mM NaCl, and 1 mM EDTA)
on ice (15 minutes), lysed through a 21-gauge needle, and
centrifuged at 14,000 rpm (4jC, 10 minutes). Supernatants
containing cytoplasmic protein extracts were removed.
One hundred microliters of buffer B (10 mM Tris–HCl,
pH 7.4, 10 mM NaCl, and 1.5 mM MgCl2), 25 ml of 5 M NaCl,
and complete miniprotease inhibitor cocktail were added
to the precipitate, incubated on ice (30 minutes), and cen-
trifuged at 14,000 rpm (4jC, 10 minutes). Supernatants
containing nuclear protein extracts were stored at 20jC
until use.
Cell Proliferation Assay
U87MG human glioblastoma cells were grown in 48-well
plates and transfected (in quadriplicates) as described
above. Cell proliferation was assessed 30 hours posttrans-
fection by measuring the incorporation of 5V-bromo-2-deox-
yuridine (BrdU; Roche Diagnostics GmbH) over 6 hours, as
previously described [12].
Oligonucleotides
Human (h)EN101, a 20-mer antisense oligonucleotide
targeted at exon 2 of human AChE mRNA, was added
to the culture medium with transfected DNA at a concentra-
tion of 2 nM, previously reported to induce preferential
Figure 1. CREB interactions with AChE splice variants affect glioblastoma proliferation. (A) Shown is a schematic presentation of the ACHE gene (as included in
the reverse sequence of the cosmid inset; accession no. AF002993) and the relevant splice variants, AChE-S and AChE-R. Exons (gray boxes) and introns (white
boxes) are marked. ACHE gene expression is regulated by a distal domain (DD), a proximal promoter (PP) that includes a CRE domain, and an intronic enhancer
(IE). In glioblastoma cells, this gene is transcribed into AChE-R and AChE-S mRNA with distinct 3 V domains [7,8]. Expression of CREB in U87MG cells cytoplasmic
(C) and nuclear (N) extracts transfected with either irrelevant DNA (Ct), AChE-R, AChE-S, or CREB expression vectors, or AChE-R and CREB together.
Transfection efficacy, assessed by GFP expression, was 25 ± 8%. Lower panel shows densitometric quantification of CREB expression in the nuclear extracts. (C)
AChE-R overexpression increases U87MG cell proliferation in an antisense suppressible manner: BrdU incorporation was assessed in U87MG cells, under various
treatments, with or without overexpressing AChE-R (black and white columns, respectively). Treatment included transfections with AChE-S or CREB expression
vectors, or treatment with the human (h) EN101 antisense oligonucleotide targeted at human AChE mRNA or with the corresponding inverse oligonucleotide
INVEN101, in both cases with or without AChE-R. Notice that both CREB and EN101 were able to suppress AChE-R– induced cell proliferation. Columns show
percent increase over control (= cells transfected with the irrelevant GFP plasmid) ± SEM; average of four duplicate transfections. *Statistically significant
difference from control (P < .005, ANOVA). Mean absorbance value (A405 /A492) for control was 0.3.
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degradation of AChE-R mRNA [9,12,13]. Antisense pene-
trance into cells was previously quantified using fluorescein-
labeled EN101. At 2 nM, virtually all treated cells include
EN101 molecules [14]. EN101’s three 3V-terminal residues
(*) were substituted with oxymethyl groups at the 2V position
(5V-CTGCGATATTTTCTT GTA*C*C*-3V). Similarly pro-
tected INVEN101, an oligonucleotide of sequence inverse
to EN101, served as control [9].
Immunoprecipitation
Cellhomogenateswereprepared [13]and incubated (over-
night, 4jC) with 2 mg of goat polyclonal antibodies targeted
to the human AChE N-terminus (Santa Cruz Biotechnology,
Santa Cruz, CA), then with 50 ml of suspended four Fast Flow
proteinGSepharosebeads (1hour, 4jC;AmershamPharma-
cia Biotech, Upsala, Sweden). Sedimented beads were
washed three times in NET buffer (50 mM Tris–HCl, pH 7.4,
150 mM NaCl, 1 mM EDTA, 0.25% gelatin, and complete
miniprotease inhibitor cocktail; Roche Diagnostics GmbH),
suspended in sample buffer, heated (95jC, 5 minutes), and
centrifuged at maximal speed to remove beads.
Immunoblot Analyses
U87MG cell homogenates prepared 24 hours posttrans-
fection, protein extracts, or immunoprecipitates prepared as
described above were separated by sodium dodecyl sulfate
polyacrylamide gel electrophoresis (SDS-PAGE; BioRad,
Hercules, CA) and blotted onto nitrocellulose membranes.
Membranes were incubated in a blocking solution (3% skim
milk, 2% bovine serum albumin [or 5% bovine serum albumin
when detecting a phosphorylated protein], 0.3% Tween-20 in
Tris-buffered saline, 1 hour, room temperature). Immunode-
tection (4jC, overnight) was with either monoclonal mouse
anti-PKCb (P2584; Sigma Chemical Co., St. Louis, MO)
diluted 1:8000, mouse anti-PKCq (Transduction Laborato-
ries, San Diego, CA) diluted 1:1000, mouse anti-RACK1
(R20620; Transduction Laboratories, Lexington, KY) diluted
1:2500, rabbit anti–phosphorylated PKC-q antibodies (dilut-
ed 1:300; Santa Cruz Biotechnology), rabbit anti-CREB
diluted 1:800 (New England Biolabs, Beverly, MA), or rabbit
anti–Ser-133 phosphorylated CREB diluted 1:600 (New
England Biolabs). Development (room temperature, 2 hours)
was with horseradish peroxidase–conjugated goat anti–
mouse or anti–rabbit antibodies diluted 1:10,000 (Jackson
Laboratories, West Grove, PA) and enhanced chemilumi-
nescence (ECL) kit (Amersham Pharmacia Biotech, UK).
Specific Inhibitors
H-89, a specific PKA inhibitor, and bisindolylmaleimide
(BIM), a specific PKC inhibitor (Calbiochem, San Diego, CA),
were used at 10 mM. Diisopropylfluorophosphate (DFP), an
organophosphate inhibitor of AChE catalytic activity, was
used at 1 mM.
AChE’s catalytic activity
AChE’s catalytic activity, measured by accumulation of
hydrolyzed acetylthiocholine (ATCh), was assessed as pre-
viously described [13].
Results
To explore the potentially interrelated role(s) of CREB and
AChE-R in controlling human glioblastoma cell proliferation
and to search for the mechanism(s) underlying such prolif-
eration, we compared transfection and antisense suppres-
sion effects with those of anticholinesterases and protein
kinase inhibitors by measuring cell proliferation and protein
levels and properties.
CREB Can Suppress AChE-R–Induced Proliferation
In human glioblastoma U87MG cells, transfection with an
AChE-R, but not an AChE-S expression vector, enhanced
BrdU incorporation by 42 ± 4% (average ± SEM; Figure 1C),
as compared to control cells transfected with the nonrelevant
pEGFP-C2 plasmid (P = .001, ANOVA). This suggested that
AChE-R’s proliferative effect is independent of AChE’s cat-
alytic activity, shared by these two AChE variants.
AChE-R is a soluble protein [7]. Thus, AChE-R transfec-
tion leads to AChE-R secretion, which may spread the
proliferative effect also to cells that do not contain the
plasmid. Therefore, the increase in proliferation surpassed
the percentage of transfected cells, which was assessed by
GFP expression as 25 ± 8%.
The transcription factor, CREB, notably mediates cellular
responses to various mitogens and stressors. CREB is
expressed in glioblastoma cells; however, its modulation in
these cells under stress was not studied extensively. CREB
transfection resulted in nuclear accumulation of its protein
product in U87MG cells (Figure 1B). Also, CREB transfection
induced irreproducible changes in BrdU incorporation, with
insignificant effects on cell proliferation. AChE activity re-
mained unchanged in cells overexpressing CREB as com-
pared to controls, although the ACHE promoter includes a
potential CREB-binding site (data not shown). In contrast,
U87MG cells cotransfected with CREB and AChE-R dis-
played suppressed cell proliferation to a nonsignificant dif-
ference from control (control levels ± 5%) (Figure 1C). CREB
levels remained high in the cotransfected cells, suggesting
an antimitogenic role for CREB over AChE-R–mediated
proliferation in astrocytes. To test the alternative possibility
—namely that both AChE-R and CREB (although to a lesser
extent) each act independently to induce cell prolifera-
tion (but contact-mediated growth control masks this cu-
mulative effect)—we cultured U87MG cells at lower
densities (10,000 and 5000 cells/well). However, in these
cultures as well, co-overexpression of AChE-R and CREB
did not increase cell proliferation as compared to control
cultures (data not shown), making this possibility highly
unlikely.
Antisense Suppression Supports the Notion of a Selective
AChE-R Proliferative Effect
EN101 selectively induces destruction of the AChE-R
mRNA transcript. At 2 nM concentration, EN101 induced
an inconsistent effect on cell proliferation, which did not
reach statistical significance. However, in U87MG cells over-
expressing AChE-R, EN101 reduced proliferation by 78%
(from 42% to 11% increase in BrdU incorporation over
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control, P < .005). The effect was sequence-specific, as the
inverse sequence, INVEN101, did not suppress AChE-R–
induced proliferation (maintaining a 35 ± 4% increase in cell
proliferation over control; Figure 1C). Thus, both gain of
function (namely, the proliferative effect induced by trans-
fections with an AChE-R, but not AChE-S expression vector)
as well as loss of function (abolition of the AChE-R prolifer-
ative effect by a selective antisense agent) support the
variant specificity of AChE-R’s proliferative effect.
AChE-R Forms Triple Complexes with RACK1 and PKCq
In neuronal cells, AChE-R forms intracellular triple com-
plexes with PKCbII and its scaffold protein, RACK1 [13].
However, immunoblot analysis failed to detect PKCb in
U87MG cell extracts (data not shown). To explore the
protein–protein interactions of AChE-R in glioblastoma cells,
we used antibodies targeted at the N-terminus of AChE for
coimmunoprecipitation tests. In cell homogenates from
AChE-R–transfected U87MG cells, these antibodies again
failed to coimmunoprecipitate PKCbII, but coimmunoprecipi-
tated both RACK1 and PKCq, a novel calcium-independent
PKC isotype previously reported as involved in astrocytoma
proliferation [15] (Figure 2). Antibodies to RACK1, which
efficiently detect it in immunoblots, failed to pull down these
multiprotein complexes. Compatible with previous reports
[13], this may be due to the corresponding epitope being
located in a site masked in the AChE-R/RACK1/PKC com-
plexes. Anti–AChE antibodies failed to precipitate any of
these proteins in monkey kidney COS1 cells, which do not
express AChE, attesting to the specificity of these analyses.
Rat pheochromocytoma (PC12) cells express both PKCb
and PKCq; however, anti–AChE antibodies pulled down
RACK1 and PKCb, but not PKCq, from homogenates of
these cells (Figure 2), suggesting that PKCb competes
successfully with PKCq in the formation of such complexes
and that the RACK1-mediated AChE-R interaction with PKC
is cell type– and PKC isoform–specific.
AChE-R Overexpression in U87MG Cells Facilitates PKCq
Phosphorylation
To test the functional significance of the in vitro–observed
AChE-R–PKCq interaction, we studied the effect of AChE-R
overexpression on PKCq phosphorylation by using selective
antibodies (Figure 3A).
Facilitated PKCq interaction with antibodies specific for
phosphorylated PKCq was reproducibly observed in extracts
of U87MG cells overexpressing AChE-R, as compared to
control cells or cells overexpressing AChE-S. This effect, as
well, appeared to be independent of AChE’s catalytic activity.
Although AChE expression is well documented in primary
human glioblastoma tumors [16,17], U87MG cells showed
only minimal endogenous AChE catalytic activity. Also,
AChE protein levels were negligible as immunolabeling of
AChE in U87MG extracts was very faint (data not shown),
likely reflecting residual levels of the protein from the serum
component of the medium the cells were grown in. Over-
expressing the AChE variants in these cells makes this
model somewhat more biologically relevant. AChE activity
was higher in cell homogenates overexpressing AChE-S;
however, PKCq phosphorylation was much more limited, as
compared with AChE-R–overexpressing cells (Figure 3B).
Thus, these data support our hypothesis that the RACK1–
AChE-R interaction, but not acetylcholine hydrolysis, facili-
tates the AChE-R–induced proliferation.
Figure 2. PKCe, but not PKC, forms triple complexes with AChE and RACK1 in U87MG cells. Shown are results of immunodetection of RACK1, PKCe, and PKC
in either U87MG, PC12, or COS1 cells immunoprecipitated with antibodies targeted to the human AChE N-terminus or PC12 whole cell homogenates. Schematic
presentations of the protein complexes specific for each cell type, as suggested by the immunoprecipitations, are drawn.
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AChE-R– Induced Proliferation Involves PKC and PKA
Phosphorylation, But Not Cholinergic Signaling
We treated AChE-R– transfected U87MG cells with
1 mM DFP, an inhibitor of AChE’s catalytic activity; H-89, a
selective PKA inhibitor [18]; or BIM, which inhibits PKC
activities [19]. DFP did not suppress the AChE-R–induced
proliferation of AChE-R transfected U87MG cells (data not
shown), supporting our conclusion that this effect is non-
catalytic. In contrast, at 10 mM, either H-89 or BIM completely
suppressed the AChE-R proliferative effect (Figure 4A),
suggesting that both PKC and PKA signaling pathways
are involved in the AChE-R– induced proliferation of
U87MG cells.
AChE-R Proliferative Effect Under PKC Inhibition of
CREB Signaling
Neither BIM nor H-89 affected U87MG proliferation under
AChE-S/CREB co-overexpression. Also, the PKA inhibitor,
H-89, had no apparent effect on U87MG cell proliferation
under AChE-R/CREB co-overexpression. In contrast, cell
proliferation increased significantly (46 ± 1.5%, P < .005)
over control in BIM-treated cells co-overexpressing AChE-R
and CREB (Figure 4A), demonstrating that BIM revoked
CREB’s suppression of AChE-R–induced proliferation, re-
trieving the full scope of the AChE-R proliferative effect. This
was compatible with the assumption that the CREB-sup-
pressive effect over AChE-R–induced U87MG cell prolifer-
ation depends on PKC activation. Indeed, CREB
phosphorylation increased in cells cotransfected with
AChE-R and CREB, suggesting an interaction between
these two signaling pathways (Figure 4B). Nevertheless,
under PKC inhibition, which prevents the suppressive effect
of CREB, AChE-R proliferative effects could be trans-
duced through the PKA-dependent pathway (Figure 4, left
upper panel ).
Discussion
Using U87MG cells, we found that the transcription factor,
CREB, and the stress-induced variant of acetylcholinester-
ase, AChE-R, contribute together to the balance between
signals promoting and suppressing the proliferation of glio-
blastoma cells. AChE-R enhances proliferation in a manner
independent of its catalytic activity, probably transduced by
either PKC- or PKA-mediated signaling pathways, and sup-
pressible by CREB as well as by an AChE-R–targeted
antisense agent. In glioblastoma cells, AChE-R interacts
with RACK1 and PKCq in a triple complex that differs from
the PKCbII-including complex of PC12 cells. Our findings are
compatible with the assumption that in glioblastoma cells
under acute situations, associated with extreme excess of
AChE-R, CREB’s regulation may fail to prevent uncontrolled
proliferation.
Transcriptional Regulation Of AChE-R–Induced Proliferation
Our findings suggest an antimitogenic role for CREB in
astrocytes and point to an intrinsic transcriptional regulation
mechanism over AChE-R–mediated proliferation. CREB
Figure 3. Enhanced PKCe phosphorylation under an excess of AChE-R, but not of AChE-S. (A) Western blot analysis showing immunodetection with anti –
phosphorylated PKCe antibodies in U87MG extracts from three different transfections with either AChE-R or AChE-S vectors. Densitometric quantification of the
p-PKCe signal is presented in the lower panel. (B) AChE’s catalytic activity (measured by accumulation of hydrolyzed acetylthiocholine, ATCh) in corresponding cell
extracts.
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is a plasticity-associated transcription factor, mediating re-
sponses to various neurotransmitters, mitogenic factors,
and differentiating factors [6]. CREB promotes proliferation
and survival of neurons and glia in the injured brain [20] and
mediates cell viability during early embryonic development
[21]. However, in smooth muscle cells, CREB activation (by
Ser-133 phosphorylation) associates with suppressed ex-
pression of multiple cell cycle regulatory genes and reduced
proliferation [6,22]. Thus, CREB may operate either as an
inducer or as a suppressor of gene expression, depending
on the signal pathway promoting its activation.
Antisense Suppression of the AChE-R Proliferative Effect
EN101 is a 2V-oxymethylated antisense oligonucleotide,
which targets a common site on the exon 2–encoded part of
AChE mRNA. EN101 selectively induces destruction of the
unstable AChE-R mRNA transcript, possibly because it can
interact only with newly transcribed AChE mRNA chains.
Whereas the relatively stable AChE-S mRNA is protected
from degradation in translatable complexes, the rapidly
emerging AChE-R mRNA transcripts are destroyed before
having the chance to get protected. Selective AChE-R
mRNA destruction by EN101 was demonstrated in the
mouse [13], rat [9], and human clinical studies [23]. Nano-
molar doses of such antisense agents attenuated cell prolif-
eration in cultured osteosarcoma cells (SaOs-2) [12] and
human hematopoietic progenitor cells [24]. Here, we report
that EN101 was able to significantly suppress the AChE-R
proliferative effect in cultured glioblastoma cells, suggesting
a role for AChE in the pathogenesis of various tumors.
Although EN101 is currently being tested in the UK and
Israel for its capacity to improve neuromuscular functioning
in myasthenic patients [23], over a dozen anti– tumor anti-
sense drugs are currently being tested for treating different
tumors, at different phases of clinical trials [25]. Further re-
search will be required to test the anti–neoplastic utility of
EN101 in the treatment of glioblastoma and/or other tumors.
Attributing AChE-R–Induced Proliferation to PKCq
AChE-R interaction with PKCbII and its scaffold protein,
RACK1, was recently reported to mediate extended conflict
behavior [13]. In glioblastoma U87MG cells, PKCq, but not
PKCb, forms triple complexes with RACK1 and AChE. The
RACK1-mediated interaction between AChE and a specific
PKC isoform thus appears to be cell type–restricted. Al-
though both PKCb and PKCq were detected in PC12 cells,
only PKCb formed AChE–RACK1 complexes in these cells,
suggesting that PKCq would interact with AChE–RACK1
complexes only in the absence of PKCb. Another possibility
is that because the complexes were formed with endoge-
nous AChE, rather than with an overexpressed specific
variant, difference in the composition of AChE variants may
contribute to the formation of these triple complexes.
In human glioblastoma cells, induction of a dominant-
negative PKCq mutant blocked cell proliferation [15]. PKCq,
furthermore, contributes to tumor development and cell
invasion in prostate cancer [26] and induces glial cell metas-
tasis by activating Erk to mediate integrin-dependent
Figure 4. CREB release of AChE-R– induced proliferation under PKC
inhibition. (A) Shown is the outcome of U87MG cell transfections with CREB,
AChE-R, or AChE-S vectors, alone (top) or together (bottom), following
treatment with either 10 M H-89, a specific PKA inhibitor (hatched bars), or
10 M BIM, a specific PKC inhibitor (filled bars). Columns represent percent
increase of BrdU incorporation over control ± SEM; average of four duplicate
transfections. *Statistically significant difference from control (P < .05,
ANOVA). (B) CREB phosphorylation increases in U87MG cells under
cotransfection with CREB and AChE-R. Immunoblot analysis was with
antibodies specific for Ser-133–phosphorylated CREB. A densitometric
quantification of the p-CREB signal is shown. (C) Proposed mechanism for
AChE-R– induced glioblastoma cell proliferation.
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adhesion and cell migration [27]. RACK1 links PKCq to
integrin b chains [28], suggesting its involvement with these
events.
PKCq’s activation and ability to respond to secondarymes-
sengers require specific phosphorylation [29]. In this study,
we show an association between PKCq phosphorylation and
AChE-R overexpression in glioblastoma cells. The AChE-R–
PKCq interaction in glioblastoma cells, as well as PKCq’s
facilitated phosphorylation, thus highlight AChE-R’s involve-
ment in a signaling pathway associated with tumor cell
proliferation and aggressiveness, supporting our notion of
AChE-R’s role in glioblastoma tumorigenesis.
AChE-R–Induced Proliferation Involves Phosphorylation,
But Not Cholinergic Signaling
Acetylcholine stimulates proliferation of rat cortical astro-
cytes and human astrocytoma cells by activating muscarinic
acetylcholine receptors [30,31]. MAPK, PKCq, and ~ were
also implicated in this process [32,33]. However, the more
aggressive glioblastoma cells lack functioning acetylcholine
receptors [34]. Together with our finding that AChE-R–
induced proliferation is refractory to DFP inhibition of AChE’s
catalytic activity, this suggests that glioblastoma proliferation
dissociates from cholinergic pathways. Within transfected
cells, the C-terminus of AChE-R confines it to the cytoplasm
[8]. There is also recent immunocytochemical evidence
demonstrating the cytosolic localization of neuronal AChE-R
[35]. To promote cell proliferation, signal transduction
pathways are hence required for inducing nuclear activation
of cell cycle effectors. We found that AChE-R–induced
proliferation involves both PKA and PKC signals. The fact
that both PKC and PKA inhibition completely abolished
AChE-R–induced proliferation raises a possibility that calls
for further exploration—that these pathways are being acti-
vated in succession following AChE-R’s signal. Moreover, as
signaling pathways can be activated and inactivated by a
number of intermediates, other pathways and mediators
should be further investigated as well.
Suppressed AChE-R Proliferative Effect Under PKC-
Induced CREB Signaling
Various growth factors, stress signals, and kinases, in-
cluding PKA, PKC, calcium/calmodulin kinase 2, and MAPK-
activated protein (MAPKAP), promote CREB activation by
Ser-133 phosphorylation, resulting in complex, at times
diverse, cellular outcomes, including cell proliferation or
quiescence, which are context- and activator-dependent
[6,11,36]. PKC-mediated CREB activation induced prolifer-
ation of early oligodendrocytes [37]. Although PKA-depen-
dent CREB activation promotes astroglia differentiation [5], it
is required for Schwann cells proliferation [38]. CREB’s
suppression of AChE-R–induced proliferation was associat-
ed with CREB/Ser-133 phosphorylation and was revoked by
PKC—but not by PKA—inhibitors, suggesting that CREB’s
antimitogenic effects are PKC-mediated, but also that
AChE-R may induce proliferation through a PKA-dependent
pathway. This is compatible with the assumption that
AChE-R–induced PKA-mediated proliferation, which would
be redundant in the presence of effective PKC-mediated
CREB activation and phosphorylation under low endoge-
nous CREB levels, can become fully expressed under PKC
inhibition and CREB overexpression: an increase in AChE-R
levels results in a PKC-mediated (according to our data,
PKCq-mediated) cell proliferation. This PKC activation is
probably PKA-dependent, as both PKC and PKA inhibitors
abolished AChE-R’s effects, suggesting that these path-
ways are activated in succession. However, because PKC
may be activated through other pathways as well, this
calls for further investigation in order to show direct PKA-
dependent PKC activation upon AChE-R signal.
PKA may also mediate cell proliferation through a CREB-
dependent pathway, as reported by others [39,40]. Our data
suggest that when activated by PKC, CREB suppresses
AChE-R–induced cell proliferation, unless AChE-R is in
extreme excess as compared to CREB’s endogenous levels.
Under PKC inhibition, both AChE-R–PKC–mediated prolif-
eration as well as PKC-mediated CREB’s inhibitory effect
are attenuated. Yet, under AChE-R excess, PKC inhibition
results in a net proliferative effect probably because AChE-R
induces proliferation through a non–PKC-dependent—
perhaps a PKA-mediated—pathway. Nevertheless, other
signaling pathways may be involved in this effect as well
(Figure 4, scheme).
In conclusion, our findings are compatible with the hy-
pothesis that CREB’s basal levels are insufficient to block the
AChE-R proliferative effect in cells with extreme excess of
AChE-R compared to CREB (e.g., under AChE-R transfec-
tion). This may increase the risk for glial tumor growth in
individuals exposed to anticholinesterases or head trauma,
both shown to induce massive AChE-R overexpression [7].
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